Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO > PEER COMPARISON
Peer Comparison      
Cipla Ltd.
Peer CompaniesPrice(Rs)Chg(Rs) Chg(%)EPS(Rs.)TTM P/EVolume(000's)1Year Return(%)Divinded YieldBook Value
Abbott India 26276.95 806.05 3.16 717.26 36.69 758-15.44 1.81 1978.48
Neuland Laboratories 11919.55 369.8 3.2 138.99 84.96 12460.1 0.1 1182.3
Sanofi Cons. Health 4189.95 118.5 2.91 104.25 40.29 571-11.79 1.79 118.26
Acutaas Chemicals 2384.5 114.95 5.06 35.66 66.86 4464791.11 0.03 160.19
Pfizer 4644.9 93.05 2.04 186.58 24.96 53013.33 3.54 921.84
Astrazeneca Pharma I 8246.85 92.35 1.13 80.36 102.74 147-2.49 0.39 305.28
RPG Life Sciences 1810.35 76.55 4.42 122.51 14.78 285-22.18 1.33 320.8
Emcure Pharma 1540 68.5 4.66 33.69 45.62 530445.04 0.2 158.99
Alkem Laboratories 5206.9 61.3 1.19 183.49 28.4 6463.05 0.87 1030.68
Jenburkt Pharma 1018 60 6.26 73.47 13.86 18034.06 1.77 389.23
Bharat Parenterals 1027.05 58.85 6.08 24.56 41.82 102.48 0.1 561.27
NGL Fine-Chem 2121.75 53.15 2.57 48.17 44.05 8885.79 0.08 452.6
Gland Pharma 1660.05 48.1 2.98 70.96 23.5 26912.96 1.09 592.08
Glaxosmithkline Phar 2325 45.15 1.98 58.85 39.34 2367-19.35 2.33 115.94
Wockhardt 1146 44.6 4.05 11.75 96.81 34924-22.43 0 169.88
Jubilant Pharmova 857.1 42.9 5.27 -1.49 0 3599-4.31 0.58 144.98
Venus Remedies 864 40.25 4.89 52.85 16.28 3144190.91 0 441.01
Kwality Pharma 1495 38.85 2.67 54.5 27.25 9868110.5 0 255.44
Mankind Pharma 1958.3 35.85 1.86 41.27 47.24 12333-17.45 0 353.77
Procter&Gamble Healt 4849.6 34.85 0.72 176.81 27.42 200-11.36 2.58 320.52
Page 1 of 9 Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.